ClinicalTrials.gg
Not yet recruitingNCT07290101Updated Dec 18, 2025

A First-in-Man Clinical Trial to Evaluate the Safety and Feasibility of ICS-Elpis in Patients With Iliac Artery Stenosis or Occlusion Lesions

An interventional study of Bioresorbable Peripheral Balloon-Expandable Covered Scaffold System in Iliac Artery Stenosis and Iliac Artery Occlusion, sponsored by Biotyx Medical (Shenzhen) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Biotyx Medical (Shenzhen) Co., Ltd. (part of LifeTech Scientific Corporation) · Not applicable, Interventional, and Device feasibility

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Constriction, Pathologic with a site in China — 37 open to participants now, 40 under way, 3 of them phase 3. Constriction, Pathologic · China.

Planned enrollment
54th of 56
15 · median 145
Started
2025
with 8 others
No phase
48 of 81
21 open now
Primary completion
2027-12
later than 30 of 39 live
Registered
73rd of 81
by date

Among the 81 studies in Constriction, Pathologic with a site in China, this one is the 54th largest by planned enrollment of the 56 interventional ones that give a count, is one of 9 that started in 2025, is one of 48 with no phase, reaches primary completion later than 30 of the 39 other live ones, and was the 73rd registered.

Constriction, Pathologic

457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.

Browse Constriction, Pathologic studies →

Open to participants now

37 of the 81 studies in Constriction, Pathologic with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Constriction, Pathologic with a site in China, or all of them as a file.
02

Study summary

This trial is a prospective, single-center, first-in-man clinical trial to evaluate the feasibility, preliminary safety and effectiveness of the Bioresorbable Peripheral Balloon-Expandable Covered Scaffold System. 15 subjects are intended to be enrolled.

Read the detailed description

Clinical follow-up visits should be conducted at before discharge, 30 days, 6 month, 9 months, and 12 months post-procedure. CTA and DUS will be performed at 6 month and 12 months post-procedure.

The primary endpoints include primary patency rate of the target lesion at 12 months post-procedure and Major Adverse Events (MAE) at 9 months post-procedure.

03

Conditions studied

  • Iliac Artery Stenosis
  • Iliac Artery Occlusion

Keywords

  • iliac artery occlusion
  • Bioresorbable Peripheral Balloon-Expandable Covered Scaffold System
  • iliac artery stenosis
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General inclusion criteria

  1. Patients with stenosis or occlusion of the common iliac artery and/or external iliac artery caused by atherosclerosis.
  2. Age between 18 - 85 years old. Male or non-pregnant female.
  3. Patients with intermittent claudication (Rutherford category 2-3) or ischemic rest pain (Rutherford category 4).
  4. Patients who can understand the purpose of the trial, voluntarily participate and sign the form, and are willing to complete the follow-up according to the protocol requirements.

Angiographic Inclusion Criteria

  1. Patients with evidence of unilateral or bilateral de novo or restenosis (non-stent treatment) lesion(s) in the common iliac artery and/or external iliac artery, with the stenosis degree of the target lesion being≥50% (including occlusion).
  2. The target lesion(s) can be successfully crossed with a guide wire and pre-dilated with an appropriately sized balloon.
  3. The target lesion(s) with reference vessel diameter between 4.0 mm and 12.0 mm, and total length of unilateral lesion(s) ≤ 100 mm (tandem lesions are allowed).
  4. Up to two ipsilateral target lesions or bilateral lesions are allowed (one target lesion per limb, with the length adhering to the unilateral criterion). Up to two stents are allowed for stent overlap per side (i.e., a maximum of two stents can be implanted per side).
  5. Patients with angiographic evidence of patent outflow vessels in the target limb, including: a healthy common femoral artery (\<50% stenosis); at least one of the deep femoral artery or superficial femoral artery is patent (\<50% stenosis); a healthy popliteal artery (\<50% stenosis); and at least one patent infrapopliteal vessel connected (\<50% stenosis).
  6. For stenotic or occlusive target lesion(s) located at the ostium of the common iliac artery without a residual stump, intervention can be achieved through kissing stent technique.

Exclusion criteria

Exclusion Criteria:

General exclusion criteria

  1. Patients with previously stented target lesion.
  2. Patients who have undergone lower extremity arterial intervention within 30 days before the index procedure, or has such intervention planned for within 30 days after the index procedure.
  3. Patients with a history of or planned ipsilateral aortoiliac bypass surgery during the index procedure.
  4. Patients who were expected to undergo amputation of the target limb before the index procedure.
  5. Patients with an aneurysm, perforation and/or dissection of the target iliac artery before the index procedure.
  6. Patients who have undergone coronary artery intervention within 30 days before the index procedure, or has such intervention planned for within 30 days after the index procedure (including the index procedure).
  7. Patients with acute myocardial infarction or angina pectoris within 30 days before the index procedure.
  8. Patients with a stroke within 3 months before the index procedure, or a stroke more than 3 months before the index procedure accompanied by severe paralysis and aphasia sequelae.
  9. Patients with known intolerance to antiplatelet, anticoagulant, or thrombolytic medications.
  10. Patients with known diseases (not related to the trial) that require indefinite or lifelong anticoagulation therapy.
  11. Patients with known allergies to aspirin, heparin, clopidogrel, contrast agent, poly(lactide), iron and its degradation products.
  12. Patients with a history of iron overload or iron disorder, such as hereditary hemochromatosis, etc.
  13. Patients with coagulation insufficiency ( count \< 80*109/L), systemic coagulation disorders or hypercoagulable tendencies.
  14. Patients with severe hepatic or renal insufficiency (serum creatinine >2 times the or on renal dialysis; or AST > 5 times the upper limit of normal).
  15. Patients with a of less than two years.
  16. Patient currently participating in another clinical trial, and have not yet completed that trial.
  17. Patients who are not suitable for participating the trial as per investigator judgement.

Angiographic Exclusion Criteria

  1. Patients with angiographic evidence of thrombus within or adjacent to the target lesion(s).
  2. Patients with a history of ipsilateral iliac artery stenting, where the distance between the previously implanted stent and the current target lesion is ≤ 5 mm.
  3. Patients with coexisting ipsilateral iliac aneurysms or abdominal aortic aneurysms.
  4. Patients in whom the internal iliac artery is patent, but implanting the stent in the target lesion will block the blood flow from entering the internal iliac artery.
  5. Patients requiring placement of a study device within 2 cm proximal to the inguinal ligament.
  6. Patients with severe calcification of the target lesion which makes it impossible for the pre-dilation balloon to reach its nominal diameter.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    ICS-Elpis

    Bioresorbable Peripheral Balloon-Expandable Covered Scaffold System

    Device: Bioresorbable Peripheral Balloon-Expandable Covered Scaffold System

Interventions

  • DeviceBioresorbable Peripheral Balloon-Expandable Covered Scaffold System

    Subjects in the arm will be treated with ICS-Elpis

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Endpoint: Primary Patency Rate of the Target Lesion

    Primary patency is defined as the peak systolic velocity ratio (PSVR) ≤2.4 assessed by duplex ultrasonography (DUS) or the stenosis degree of the target lesion≤70% assessed by CTA; if there is a conflict between the results of DUS and CTA, the CTA result should prevail.

    Time frame: At12 months

  2. Primary Safety Endpoint: Rate of Major Adverse Events

    The endpoint is a composite endpoint includes 1. Device or procedure-related death within 30 days 2. Myocardial Infarction (MI) within 30 days, 3. Target lesion revascularization (TLR) within 9 months, 4. Major amputation above the ankle joint of the target limb, resulting from a vascular event within 9 months.

    Time frame: At 30 days (for death and MI) and 9 months (for TLR and major amputation)

07

Study locations

1 site
  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200120, China
    • Meng Ye, PHD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Dec 2027, 23 months later.

Of 43 industry-sponsored interventional studies with no phase under Constriction, Pathologic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's planned 23 months is below that.

Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 18 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Dec 18, 2025
StartEst.
Dec 8, 2025
Primary completionEst.
Dec 1, 2027
CompletionEst.
Mar 1, 2028
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07290101
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Dec 8, 2025 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Dec 18, 2025

Study contacts

Ying Xia
Contact
sophia.xia@biotyxmed.com
0755-23221096

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion